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Abstract: We report a case of a 52-year-old woman with a 1-year history of rheumatoid arthritis-associated interstitial lung disease referred to 
hospital because of aggravated pulmonary symptoms in spite of intensive treatment including prednisone, azathioprine and triptergium glycoside. 
We subsequently initiated treatment with 25 mg of etanercept, subcutaneously injected twice weekly. Following 6 months of therapy with this agent, 
sustained improvement in dyspnea, cough was reported by the patient and respiratory function test showed marked improvement. The improvement 
was confirmed by reduced middle and lower lung markings on chest radiography and high-resolution CT scan. This report suggests etanercept may be 
effective in the treatment of rheumatoid arthritis-associated interstitial lung disease.
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Introduction
Although tumor necrosis factor (TNF)-α inhibitors 
have  been  used  for  the  treatment  of  patients  with 
rheumatoid arthritis for more than a decade,1–3 their 
effect on RA-associated ILD (rheumatoid arthritis—
associated interstitial lung disease) have been rarely 
reported.
TNF-α is one of most important cytokines in the 
early immune response to a variety of inflammatory 
disorders,  and  is  a  critical  mediator  in  the  patho-
genesis of pulmonary fibrosis.4 TNF-α can directly 
stimulate the secretion of matrix proteins, increase 
fibroblast  proliferation,  and  promote  induction  of 
matrix-degrading gelatinases that can facilitate fibro-
blast migration to site of injury.5 Increased expression 
of TNF-α gene is observed in fibrotic human lungs 
as well as animal models of lung fibrosis, and inhi-
bition of TNF-α expression can significantly reduce 
the  incidence  of  pulmonary  fibrosis.6  Therefore, 
TNF-α inhibitors have potential for the treatment of   
RA-associated ILD.
Here we report a case of RA-associated ILD whose 
condition was improved after etanercept (a recombi-
nant TNF- α blocker) treatment.
case Report
A 52-year-old woman first experienced knee pain and 
swelling bilaterally in May 2002, followed by grad-
ual emergence of pain and swelling in wrist, meta-
carpophalangeal and proximal interphalangeal joints 
in both hands, with morning stiffness lasting more 
than one hour. In August 2002, rheumatoid arthritis 
was confirmed. Methotrexate (MTX) (10 mg/w) plus 
leflunomide (10 mg/d) were used to control her dis-
ease. Approximately a year later the patient stopped 
her drugs because of relieved joint symptoms. She 
was admitted to hospital in June 2006 for aggravation 
of joint symptoms with irregular low heat, cough dur-
ing the preceding two months.
Physical examinations disclosed fine moist rales in 
the lower location of the lungs, tenderness and swelling 
at both knees and both wrists, and toe joints deformi-
ties. Laboratory testing demonstrated an erythrocyte 
sedimentation rate of 66 mm/h, a C-reactive protein 
of 50.30 mg/L, a rheumatoid factor of 21.9 IU/mL, 
an anti-CCP antibody of 58 RU/mL, but negative for 
antinuclear antibodies. High-resolution CT scan of 
the chest showed lung markings increased, part of the 
grid-like changes, interlobular septa thickening, and 
patchy density- enhanced shadow. Pulmonary func-
tion tests demonstrated a slight restrictive ventilation 
dysfunction with severe small airway obstruction, but 
the diffusing capacity was normal. The patients had no 
history of pulmonary disease and had no other medi-
cal problems. There was no history of exposure to 
any known occupational irritant or birds. She had no 
history of smoking, and denied a history of illicit drug 
use or alcohol abuse a diagnosis of RA-associated 
 ILD was made.
The  patient  received  the  following  medications 
at  presentation:  prednisone,  30  mg/d;  azathioprine 
100 mg/d, triptergium glycoside 30 mg/d. After leav-
ing hospital prednisone dosage gradually reduced to 
10  mg/d.  Her  joint’s  condition  was  improved,  but 
the symptoms of cough and expectoration were not 
improved. In January 2007, the patient was admitted 
to hospital again because of a repeated cough with. 
On  examination  of  the  lungs  there  were  moderate 
moist sounds at both bases. High-resolution CT scan 
of the chest showed bilateral lung interstitial lesions 
and emphysema, mediastinal lymphadenopathy. Pul-
monary  function  tests  revealed  mixed  ventilatory 
disorder, severe obstruction in small airway function 
(VC 73.0%, FEV 69.2%), small reduction in diffus-
ing capacity (TLCO/VA 69.2%).
In February 2007, she began receiving 25 mg of 
etanercept,  subcutaneously  injected  twice  weekly, 
along with prednisone (10 mg/d). During six –month 
treatment she was followed up monthly. We found 
that her right-side basilar moist rales disappeared and 
left-side basilar moist rales could still be detected. 
Chest  radiography  showed  middle  and  lower  lung 
markings  were  reduced  and  the  marked  improve-
ments were also confirmed by high-resolution CT. 
In July 2007 pulmonary function tests suggested a 
slight restrictive ventilation dysfunction, with mod-
erate small airway function obstruction (VC 76.7%, 
FEV 72.9%) and normal diffusion capacity (TLCO/
VA 89.2%). Before and after the treatment of etaner-
cept, her arthritis activity has been quiescent. 
Discussion
This is the first report documenting RA-associated 
ILD  treated  with  etanercept  in  China.  We  found 
that  pulmonary  function  in  a  female  patient  with 
RA-associated  ILD  was  improved  after  etanercept Treatment with etanercept in RA-Associated ILD
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treatment for 6 months. Symptoms and signs were 
also ameliorated.
ILD is the most common manifestation of pulmo-
nary disease in rheumatoid arthritis which severely 
affects  prognosis  of  rheumatoid  arthritis,  and  its 
secondary pulmonary fibrosis is one of the causes 
of  death.  However,  the  conventional  treatments  of 
ILD associated to RA are not effective, and some 
new drugs such as interferon-γ, pirfenidone, acetyl-
cysteine, endothelin receptor antagonist, 5-lipoxyge-
nase inhibitor are still in the stages of clinical trials.7
In 2002, Vassallo et al8 first treated a patient with 
RA-associated ILD for 1 yr with anti-tumor necro-
sis factor-α infliximab. The patient is a 71-year-old 
man with a 3-year history of seropositive rheumatoid 
arthritis. Approximately a year following the onset of 
joint symptoms, progressive dyspnea and dry cough 
appeared.  Lung  examination  revealed  fine  Velcro-
type crepitations at the bases of both lungs. Labora-
tory testing demonstrated a PO2 at rest of 75 mm Hg, 
which declined to 51 mm Hg following mild exer-
cise.  Chest  radiography  and  high-resolution  CT 
scan show pulmonary fibrosis with honeycombing. 
Following 1 year of therapy with infliximab, along 
with the improvement in joint symptoms, the patient 
sustained improvements in dyspnea, dry cough, and 
exercise tolerance. Pulmonary function demonstrated 
a normal saturation at rest and a saturation decline to 
only 90% following mild exercise.
In 2004, Bargagli et al9 also reported a patient with 
rheumatoid  arthritis  and  pulmonary  fibrosis  whose 
condition was improved after 15 months of infliximab 
treatment. Lung function tests (LFT) showed increases 
of 17% in TLCO (from 65% to 82%), and 11% in 
VC (from 73% to 84%); in contrast, high-resolution 
CT scan of the chest, which showed bibasilar man-
tellar  fibrosis  with  honeycombing,  was  not  altered 
after 15 months of therapy. Similar to our case, these 
results suggests a tumor necrosis factor-α inhibitor 
may be more effective on acute exudative lesions of 
RA-associated ILD by improving lung function, but 
has poor effects on chronic pulmonary fibrosis. It is 
expected to have a better efficacy if used at the early 
stage of RA-associated ILD.
It has been documented that methotrexate (MTX) 
can induce ILD whose frequency is around 1%–5%.10 
MTX induced- ILD is characterized by the occult onset 
after MTX use and improvement after stopping while 
recurrence of lung symptoms after repeated use. It is dif-
ficult to distinguish it from RA-associated ILD from 
clinic and imaging feathers. Although having a history 
of MTX treatment, our patient was treated only for 1 
year, 2 years before receiving a diagnosis of RA-asso-
ciated ILD. It is clear that MTX use cannot explain the 
occurrence of ILD, because MTX had been stopped 
for nearly 4 years, and the patient’s diffuse capacity 
had not been improved until using etanercept.
It has been reported that etanercept can induce ILD 
or its aggravation.11 However, our patient have ILD 
before etanercept, and her condition improved mark-
edly after etanercept. Triptergium is a chinese herb 
which is used in chronic inflammatory disorders, we 
have not find any article reporting triptolide can induce 
ILD or its aggravation through a MEDLINE search.
In conclusion, this study suggests etanercept may 
be effective in the treatment of RA-associated ILD. 
This needs to be confirmed by future double-blind, 
randomized controlled trials.
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